Buprenorphine depot - Camurus

Drug Profile

Buprenorphine depot - Camurus

Alternative Names: Buprenorphine FluidCrystal® injection depot; CAM 2048; CAM-2038

Latest Information Update: 13 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Camurus
  • Developer Braeburn Pharmaceuticals; Camurus
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Opioid abuse
  • Phase III Pain
  • Phase I/II Postoperative pain

Most Recent Events

  • 16 Jul 2018 The US FDA assigns PDUFA action date of (26/12/2018) for buprenorphine depot (CAM 2038) for Opioid abuse
  • 29 Jun 2018 Camrus expects marketing approvals for CAM 2038 in Europe, USA and Australia in second half of 2018
  • 12 Jun 2018 Camurus enters into a commercialization agreement with Medison Pharma for buprenorphine depot in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top